Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Paxlovid by Year
Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — International operational (constant-currency) YoY (%) (%)
Pfizer Paxlovid: -57.0% in FY2025, unchanged from a year earlier.
Latest, FY2025
-57.0%
Period ended Dec 31, 2025
Change on a year earlier
0.0 pts
-57.0% in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Where the FY2025 figure comes from
“|| Paxlovid (d) | 2,362 | 5,716 | (59%) | (59%) | 1,891 | 4,616 | (59%) | 470 | 1,100 | (57%) | (57%)”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Paxlovid (nirmatrelvir/ritonavir oral COVID-19 treatment) — International operational (constant-currency) YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | -57.0% | 0.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | -57.0% | -39.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | -18.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
Cite this data
StockData. (2026). Pfizer Paxlovid (%), annual FY2023–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/paxlovid-oper-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.